Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dow-Chung Chi

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Anticancer Research|September 21, 2012
Gemcitabine-induced pulmonary toxicityDow-Chung Chi, Frances Brogan, Ithamar Turenne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2020
An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate CancerMichael Brave, Chana Weinstock, Jamie R Brewer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2017
FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing RegimenAmy Barone, Dow-Chung Chi, Marc R Theoret, et al.
Breast Cancer Research and Treatment|June 25, 2021
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancerMatthew Kearney, Lauren Franks, Shing Lee, et al.
The Lancet. Oncology|January 24, 2018
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysisJulia A Beaver, Maitreyee Hazarika, Flora Mulkey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2025
FDA Approval Summary: Niraparib Plus Abiraterone Acetate Fixed Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate CancerWilliam F Maguire, Dow-Chung Chi, Sundeep Agrawal, et al.
The Lancet. Oncology|July 26, 2021
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trialsJaleh Fallah, Lijun Zhang, Anup Amatya, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Anticancer Research|September 21, 2012
Gemcitabine-induced pulmonary toxicityDow-Chung Chi, Frances Brogan, Ithamar Turenne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2020
An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate CancerMichael Brave, Chana Weinstock, Jamie R Brewer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2017
FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing RegimenAmy Barone, Dow-Chung Chi, Marc R Theoret, et al.
Breast Cancer Research and Treatment|June 25, 2021
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancerMatthew Kearney, Lauren Franks, Shing Lee, et al.
The Lancet. Oncology|January 24, 2018
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysisJulia A Beaver, Maitreyee Hazarika, Flora Mulkey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2025
FDA Approval Summary: Niraparib Plus Abiraterone Acetate Fixed Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate CancerWilliam F Maguire, Dow-Chung Chi, Sundeep Agrawal, et al.
The Lancet. Oncology|July 26, 2021
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trialsJaleh Fallah, Lijun Zhang, Anup Amatya, et al.
Pageof 1